WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H524833
CAS#: 186430-23-9
Description: CP-320626 is a potent inhibitor, synergistic with glucose, of human liver glycogen phosphorylase a (LGPa). It is a possible target for type 2 diabetes therapy. CP320626 is also a potent inhibitor of human muscle GPa.
Hodoodo Cat#: H524833
Name: CP-320626
CAS#: 186430-23-9
Chemical Formula: C23H23ClFN3O3
Exact Mass: 443.14
Molecular Weight: 443.900
Elemental Analysis: C, 62.23; H, 5.22; Cl, 7.99; F, 4.28; N, 9.47; O, 10.81
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: CP-320626; CP320626; CP 320626.
IUPAC/Chemical Name: 1H-Indole-2-carboxamide, 5-chloro-N-((1S)-1-((4-fluorophenyl)methyl)-2-(4-hydroxy-1-piperidinyl)-2-oxoethyl)-
InChi Key: YDCGVASFVACWKF-NRFANRHFSA-N
InChi Code: InChI=1S/C23H23ClFN3O3/c24-16-3-6-19-15(12-16)13-20(26-19)22(30)27-21(11-14-1-4-17(25)5-2-14)23(31)28-9-7-18(29)8-10-28/h1-6,12-13,18,21,26,29H,7-11H2,(H,27,30)/t21-/m0/s1
SMILES Code: O=C(C(N1)=CC2=C1C=CC(Cl)=C2)N[C@@H](CC3=CC=C(F)C=C3)C(N4CCC(O)CC4)=O
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 443.90 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Ma D, Wang J, Zhao Y, Lee WN, Xiao J, Go VL, Wang Q, Recker RR, Xiao GG. Inhibition of glycogen phosphorylation induces changes in cellular proteome and signaling pathways in MIA pancreatic cancer cells. Pancreas. 2012 Apr;41(3):397-408. doi: 10.1097/MPA.0b013e318236f022. PubMed PMID: 22158071; PubMed Central PMCID: PMC3306546.
2: Vizán P, Sánchez-Tena S, Alcarraz-Vizán G, Soler M, Messeguer R, Pujol MD, Lee WN, Cascante M. Characterization of the metabolic changes underlying growth factor angiogenic activation: identification of new potential therapeutic targets. Carcinogenesis. 2009 Jun;30(6):946-52. doi: 10.1093/carcin/bgp083. Epub 2009 Apr 15. PubMed PMID: 19369582.
3: Gregus Z, Németi B. Glutathione-dependent reduction of arsenate by glycogen phosphorylase responsiveness to endogenous and xenobiotic inhibitors. Toxicol Sci. 2007 Nov;100(1):44-53. Epub 2007 Aug 9. PubMed PMID: 17693424.
4: Ekins S, Mankowski DC, Hoover DJ, Lawton MP, Treadway JL, Harwood HJ Jr. Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors. Drug Metab Dispos. 2007 Mar;35(3):493-500. Epub 2006 Dec 28. Erratum in: Drug Metab Dispos. 2007 Jul;35(7):1246. PubMed PMID: 17194716.
5: Ercan-Fang N, Taylor MR, Treadway JL, Levy CB, Genereux PE, Gibbs EM, Rath VL, Kwon Y, Gannon MC, Nuttall FQ. Endogenous effectors of human liver glycogen phosphorylase modulate effects of indole-site inhibitors. Am J Physiol Endocrinol Metab. 2005 Sep;289(3):E366-72. Epub 2005 Mar 29. PubMed PMID: 15797986.
6: Harwood HJ Jr, Petras SF, Hoover DJ, Mankowski DC, Soliman VF, Sugarman ED, Hulin B, Kwon Y, Gibbs EM, Mayne JT, Treadway JL. Dual-action hypoglycemic and hypocholesterolemic agents that inhibit glycogen phosphorylase and lanosterol demethylase. J Lipid Res. 2005 Mar;46(3):547-63. Epub 2004 Dec 16. PubMed PMID: 15604516.
7: Lee WN, Guo P, Lim S, Bassilian S, Lee ST, Boren J, Cascante M, Go VL, Boros LG. Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment. Br J Cancer. 2004 Dec 13;91(12):2094-100. PubMed PMID: 15599384; PubMed Central PMCID: PMC2409791.
8: Oikonomakos NG, Chrysina ED, Kosmopoulou MN, Leonidas DD. Crystal structure of rabbit muscle glycogen phosphorylase a in complex with a potential hypoglycaemic drug at 2.0 A resolution. Biochim Biophys Acta. 2003 Apr 11;1647(1-2):325-32. PubMed PMID: 12686153.
9: Dubbelhuis PF, Van Sluijters DA, Blommaart EF, Gustafson LA, Van Woerkom GM, Herling AW, Burger HJ, Meijer AJ. Inhibition of autophagic proteolysis by inhibitors of phosphoinositide 3-kinase can interfere with the regulation of glycogen synthesis in isolated hepatocytes. Biochem J. 2002 Dec 15;368(Pt 3):827-33. PubMed PMID: 12371905; PubMed Central PMCID: PMC1223050.
10: Andersen B, Westergaard N. The effect of glucose on the potency of two distinct glycogen phosphorylase inhibitors. Biochem J. 2002 Oct 15;367(Pt 2):443-50. PubMed PMID: 12099891; PubMed Central PMCID: PMC1222892.
11: Oikonomakos NG, Zographos SE, Skamnaki VT, Archontis G. The 1.76 A resolution crystal structure of glycogen phosphorylase B complexed with glucose, and CP320626, a potential antidiabetic drug. Bioorg Med Chem. 2002 May;10(5):1313-9. PubMed PMID: 11886794.
12: Gustafson LA, Neeft M, Reijngoud DJ, Kuipers F, Sauerwein HP, Romijn JA, Herling AW, Burger HJ, Meijer AJ. Fatty acid and amino acid modulation of glucose cycling in isolated rat hepatocytes. Biochem J. 2001 Sep 15;358(Pt 3):665-71. PubMed PMID: 11535127; PubMed Central PMCID: PMC1222100.
13: Oikonomakos NG, Skamnaki VT, Tsitsanou KE, Gavalas NG, Johnson LN. A new allosteric site in glycogen phosphorylase b as a target for drug interactions. Structure. 2000 Jun 15;8(6):575-84. PubMed PMID: 10873856.
